Investigational drug · Phase 2
KDT-3594
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Parkinson Disease.
Phase 2Last checked: Nov 20, 2026Latest source record: Sep 10, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
4
Any phase or sponsor naming "KDT-3594"
First trial start
2024
Dec 16, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "KDT-3594", any sponsor or status.
Conditions studied
As listed on its trial records.
- Parkinson Disease
Approved drugs for the same conditions: Parkinson's disease · Neurology
Largest trials
Live from ClinicalTrials.gov: studies naming "KDT-3594" as an intervention, largest first.
- A Late Phase II Clinical Trial of KDT-3594 in Patients With Parkinson's DiseasePivotal-lookingCompleted
Kissei Pharmaceutical Co., Ltd.Industry
NCT06722729 · 178 participants · Start Dec 16, 2024 · Primary completion Jan 14, 2026
Drug: KDT-3594; Placebo · For: Parkinson Disease
Sites: Tokyo and Other Japanese Cities, Japan
Kissei Pharmaceutical Co., Ltd.Industry
NCT03845387 · 74 participants · Start Feb 26, 2019 · Primary completion Feb 21, 2020
Drug: KDT-3594; Pramipexole · For: Parkinson Disease
Sites: Multiple Locations, Japan
Kissei Pharmaceutical Co., Ltd.Industry
NCT03068481 · 36 participants · Start Feb 20, 2017 · Primary completion Aug 13, 2018
Drug: KDT-3594; Placebo · For: Parkinson Disease
Sites: Kyushu and Other Regions, Japan
Kissei Pharmaceutical Co., Ltd.Industry
NCT04867551 · 7 participants · Start May 15, 2021 · Primary completion Sep 6, 2021
Drug: KDT-3594 · For: Parkinson Disease
Sites: Multiple Locations, Japan
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Parkinson Disease
- RadotinibSupect, IY5511Phase 33 trials
Il-Yang Pharm. Co., Ltd. · Chronic Myeloid Leukemia, Chronic Phase, CML, Chronic Phase, CML, Refractory
- CVN424Phase 32 trials
Cerevance · Parkinson Disease, Parkinson's Disease
- BHV-8000Phase 31 trial
Biohaven Therapeutics Ltd. · Parkinson Disease
- Human Dopaminergic Progenitor CellsNouvNeu001Phase 23 trials
iRegene Therapeutics Co., Ltd. · Parkinson Disease, Parkinson Disease (PD)
- AB-1005Phase 22 trials
AskBio Inc · PARKINSON DISEASE (Disorder), Parkinson Disease
- DNL151BIIB122Phase 22 trials
Denali Therapeutics Inc. · Parkinson Disease
- HBI-002Phase 22 trials
Hillhurst Biopharmaceuticals, Inc. · Parkinson Disease, Anemia, Sickle Cell
- VutiglabridinHSG4112Phase 22 trials
Glaceum · Knee Osteoarthritis (Knee OA), Parkinson Disease
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.